1. Home
  2. FFIN vs ERAS Comparison

FFIN vs ERAS Comparison

Compare FFIN & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Financial Bankshares Inc.

FFIN

First Financial Bankshares Inc.

HOLD

Current Price

$34.79

Market Cap

4.9B

Sector

Finance

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$19.44

Market Cap

4.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FFIN
ERAS
Founded
1890
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
4.0B
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
FFIN
ERAS
Price
$34.79
$19.44
Analyst Decision
Hold
Strong Buy
Analyst Count
2
12
Target Price
$36.50
$14.25
AVG Volume (30 Days)
896.0K
5.6M
Earning Date
04-16-2026
05-08-2026
Dividend Yield
2.39%
N/A
EPS Growth
13.46
36.23
EPS
0.50
N/A
Revenue
N/A
N/A
Revenue This Year
$17.16
N/A
Revenue Next Year
$6.61
N/A
P/E Ratio
$69.76
N/A
Revenue Growth
N/A
N/A
52 Week Low
$28.12
$1.33
52 Week High
$38.12
$24.28

Technical Indicators

Market Signals
Indicator
FFIN
ERAS
Relative Strength Index (RSI) 52.68 59.92
Support Level $31.30 $17.63
Resistance Level $35.77 $24.28
Average True Range (ATR) 0.76 1.30
MACD -0.05 -0.09
Stochastic Oscillator 30.34 46.33

Price Performance

Historical Comparison
FFIN
ERAS

About FFIN First Financial Bankshares Inc.

First Financial Bankshares Inc is a financial and bank holding company. The company operates one line of business (community banking) located in a single geographic area (Texas). The company conducts a full-service commercial banking business through its subsidiaries. The loan portfolio segments of the company include Commercial and Industrial, Municipal, Agricultural, Construction and Development, Farm, Non-Owner Occupied and Owner Occupied Commercial Real Estate, Residential, Consumer Auto and Consumer Non-Auto.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: